Focal segmental glomerular sclerosis can be effectively treated using an intensive B-cell depletion therapy

Area of Science:

• Nephrology
• Immunology
• Pharmacology

Background:

• Focal segmental glomerular sclerosis (FSGS) is a complex kidney disorder with various forms, often unresponsive to standard treatments like steroids.
• Rituximab has shown limited success in adult FSGS patients, prompting the investigation of alternative therapeutic strategies.
• Previous studies indicated a need for enhanced treatment protocols for FSGS, particularly in cases with extensive podocyte effacement and treatment resistance.

Purpose of the Study:

• To evaluate the efficacy of a combination therapy involving rituximab, cyclophosphamide, and glucocorticoids in adult patients with FSGS.
• To assess the impact of this protocol on proteinuria, serum creatinine levels, and renal function in patients with steroid-dependent or frequently relapsing FSGS.
• To determine the safety and tolerability of the proposed therapeutic regimen.

Main Methods:

• Seven adult patients with extensive podocyte effacement and recurrent relapses or steroid dependence were enrolled prospectively.
• The treatment protocol consisted of six administrations of rituximab, two of intravenous cyclophosphamide, and concurrent glucocorticoids.
• Patient outcomes were monitored for changes in serum creatinine, proteinuria, and renal function over a 12-month period, with some follow-up extending to 52 months.

Main Results:

• Median serum creatinine levels significantly decreased from baseline at 3, 6, and 12 months post-treatment.
• Three out of five patients with renal failure experienced a return to normal kidney function.
• Median proteinuria decreased substantially, with five of seven patients achieving partial response and becoming non-nephrotic within 12 months.

Conclusions:

• Intensive B-cell depletion therapy combined with cyclophosphamide and glucocorticoids can reverse nephrotic syndrome in adult patients with steroid-dependent or frequently relapsing FSGS.
• The therapeutic protocol demonstrated significant improvements in renal function and proteinuria, suggesting a potential new treatment avenue.
• The treatment was well-tolerated, with no serious late adverse events observed, highlighting its safety profile.